Small molecule inhibition of the KRAS PDEd interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S.A., Triola, G., Wittinghofer, A., Bastiaens, P.I., Waldmann, H.(2013) Nature 497: 638-642
- PubMed: 23698361 
- DOI: 10.1038/nature12205
- Primary Citation of Related Structures:  
- PubMed Abstract: 
The KRAS oncogene product is considered a major target in anticancer drug discovery. However, direct interference with KRAS signalling has not yet led to clinically useful drugs. Correct localization and signalling by farnesylated KRAS is regulated b ...









